Dr. Strosberg on the Results of the NETTER-1 Trial

Jonathan Strosberg, MD
Published: Wednesday, Sep 07, 2016



Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

The NETTER-1 trial compared Lutathera (lutetium Lu 177 dotatate) with high-dose octreotide (Sandostatin) in patients with midgut neuroendocrine tumors (NETs). It is the first phase III prospective randomized clinical trial evaluating Lutathera in this patient population.

The primary endpoint of the trial was progression-free survival (PFS). The study demonstrated a 79% improvement in the hazard ratio for PFS. The PFS for the control arm (high-dose octreotide) was 8 months. At the time of the primary endpoint analysis, PFS had not yet been reached with Lutathera.

Results of the trial also demonstrated a 60% improvement in overall survival (OS) (P = .004). While this result did not reach the threshold for statistical significance, it is only an interim analysis, and Strosberg remains hopeful that a final analysis of OS will see clinically and statistically significant improvement.


Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

The NETTER-1 trial compared Lutathera (lutetium Lu 177 dotatate) with high-dose octreotide (Sandostatin) in patients with midgut neuroendocrine tumors (NETs). It is the first phase III prospective randomized clinical trial evaluating Lutathera in this patient population.

The primary endpoint of the trial was progression-free survival (PFS). The study demonstrated a 79% improvement in the hazard ratio for PFS. The PFS for the control arm (high-dose octreotide) was 8 months. At the time of the primary endpoint analysis, PFS had not yet been reached with Lutathera.

Results of the trial also demonstrated a 60% improvement in overall survival (OS) (P = .004). While this result did not reach the threshold for statistical significance, it is only an interim analysis, and Strosberg remains hopeful that a final analysis of OS will see clinically and statistically significant improvement.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x